Galapagos Announces Agreement with United States Environmental Protection Agency
News Apr 18, 2007
BioFocus DPI will provide chemical procurement and compound management services as part of the EPA's ToxCast™ Program. The contract covers a period of up to five years and has a total value of up to €6.3 million.
Under the agreement, which marks the first new compound management contract since the acquisition of the DPI assets in July 2006, BioFocus DPI will acquire, analyze, store, format and deliver specific compounds to a variety of sites selected by the EPA. The total size of the collection will be determined at the EPA's discretion.
"We are pleased that the EPA has selected BioFocus DPI to carry out the chemical procurement and management activities of the ToxCast™ program," stated Onno van de Stolpe, Chief Executive Officer of Galapagos.
"The contract awarded by the EPA resulted from a competitive contracting process, which indicates that we are among the premier providers of compound management services based on both capabilities and price competitiveness," Stolpe said.
"The EPA is an important new client to our compound management activities," stated Christopher Newton, Senior Vice President of BioFocus DPI. "We will apply many of the same skills and processes to this program that we have used and developed for the NIH's Roadmap Initiative."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE